Aurora Cannabis (ACB) announced an investment over five years into operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany. Building on best practices proven at Aurora’s Canadian facilities, these improvements aim to increase flower growth capacity, product quality and drive cost efficiency. With the goal of maximizing cultivation volume, the upgrades include commissioning additional grow rooms, new irrigation and lighting systems in existing rooms, and transitioning to hang dry and dry trim. Aurora Leunais one of only three licensed cultivation facilities in the country. Aurora Leuna currently grows cultivars under the IndiMed brand, and this expansion will enable the site to grow additional cultivars available from Aurora’s genetics library.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Largest borrow rate increases among liquid names
- Aurora Cannabis announces launch of Whistler Cannabis Co. in Australia
- Trump Trade: Nvidia, AMD said to pay U.S. cut from China chip sales
- Trump debates on reclassifying marijuana as less dangerous drug, WSJ says
- Aurora Cannabis Announces 2025 AGM Results and Board Changes